Beam Therapeutics (BEAM) Financials

$17.89 -0.19 (-1.05%)

Closing price 06/11/2025 04:00 PM Eastern

Extended Trading

$18.27 +0.38 (+2.15%)

As of 04:47 AM Eastern

Annual Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-91	-196	-371	-289	-133	-377
Consolidated Net Income / (Loss)	-78	-195	-371	-289	-133	-377
Net Income / (Loss) Continuing Operations	-78	-195	-371	-289	-133	-377
Total Pre-Tax Income	-78	-195	-371	-260	-131	-377
Total Operating Income	-75	-133	-392	-338	-176	-416
Total Gross Profit	0.02	0.02	52	61	378	64
Total Revenue	0.02	0.02	52	61	378	64
Operating Revenue	0.02	0.02	52	61	378	64
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	75	133	444	399	554	479
Selling, General & Admin Expense	21	30	57	88	117	112
Research & Development Expense	55	103	387	312	437	368
Total Other Income / (Expense), net	-3.17	-62	22	78	45	39
Interest Expense	-2.23	-1.05	0.01	-15	-47	-49
Other Income / (Expense), net	-5.40	-63	22	63	-1.35	-10
Income Tax Expense	-	0.00	0.00	3.41	1.37	0.04
Other Gains / (Losses), net	-	0.00	0.00	-26	0.00	0.00
Basic Earnings per Share	($14.05)	($4.19)	($5.77)	($4.13)	($1.72)	($4.58)
Weighted Average Basic Shares Outstanding	6.48M	46.73M	64.23M	70.02M	77.15M	82.31M
Diluted Earnings per Share	($14.05)	($4.19)	($5.77)	($4.13)	($1.72)	($4.58)
Weighted Average Diluted Shares Outstanding	6.48M	46.73M	64.23M	70.02M	77.15M	82.31M
Weighted Average Basic & Diluted Shares Outstanding	6.48M	46.73M	68.73M	72.40M	81.66M	83.69M

This table shows Beam Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-110	-38	-96	-83	-96	143	-99	-91	-97	-90	-109
Consolidated Net Income / (Loss)	-110	-38	-96	-83	-96	143	-99	-91	-97	-90	-109
Net Income / (Loss) Continuing Operations	-110	-38	-96	-83	-96	143	-99	-91	-97	-90	-109
Total Pre-Tax Income	-82	-37	0.00	-83	-96	48	0.00	-91	-97	-189	-109
Total Operating Income	-91	-89	-99	-102	-108	133	-104	-105	-107	-100	-119
Total Gross Profit	16	20	24	20	17	316	7.41	12	14	30	7.47
Total Revenue	16	20	24	20	17	316	7.41	12	14	30	7.47
Operating Revenue	16	20	24	20	17	316	7.41	12	14	30	7.47
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	107	109	123	122	125	183	112	117	121	130	127
Selling, General & Admin Expense	22	23	23	25	25	43	27	30	27	29	28
Research & Development Expense	85	86	100	98	100	140	85	87	94	101	99
Other Special Charges / (Income)	-	-	-	-	-	-	-	-	-	-	0.03
Total Other Income / (Expense), net	9.64	52	2.47	19	12	11	5.46	14	9.84	9.68	10
Interest Expense	-4.98	-7.61	-9.96	-12	-13	-12	-12	-14	-12	-11	-9.86
Other Income / (Expense), net	4.66	44	-7.49	7.42	-0.52	-0.76	-6.39	-0.31	-2.29	-1.25	0.18
Basic Earnings per Share	($1.56)	($0.54)	($1.33)	($1.08)	($1.22)	$1.91	($1.21)	($1.11)	($1.17)	($1.09)	($1.24)
Weighted Average Basic Shares Outstanding	70.34M	70.02M	72.27M	76.34M	79.02M	77.15M	81.70M	82.31M	82.41M	82.31M	87.98M
Diluted Earnings per Share	($1.56)	($0.54)	($1.33)	($1.08)	($1.22)	$1.91	($1.21)	($1.11)	($1.17)	($1.09)	($1.24)
Weighted Average Diluted Shares Outstanding	70.34M	70.02M	72.27M	76.34M	79.02M	77.15M	81.70M	82.31M	82.41M	82.31M	87.98M
Weighted Average Basic & Diluted Shares Outstanding	70.47M	72.40M	76.22M	79.20M	81.50M	81.66M	82.31M	82.42M	82.81M	83.69M	100.56M

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-97	126	396	-327	199	-155
Net Cash From Operating Activities	-72	-96	-66	23	-149	-347
Net Cash From Continuing Operating Activities	-72	-96	-66	23	-149	-347
Net Income / (Loss) Continuing Operations	-78	-195	-371	-289	-133	-377
Consolidated Net Income / (Loss)	-78	-195	-371	-289	-133	-377
Depreciation Expense	3.50	4.74	7.45	14	20	22
Amortization Expense	-0.92	0.12	-0.08	-0.98	-20	-13
Non-Cash Adjustments To Reconcile Net Income	12	92	-109	378	99	120
Changes in Operating Assets and Liabilities, net	-8.17	2.20	406	-80	-116	-99
Net Cash From Investing Activities	-67	-100	-294	-461	72	185
Net Cash From Continuing Investing Activities	-66	-99	-294	-461	72	185
Purchase of Property, Plant & Equipment	-13	-16	-47	-49	-34	-8.95
Purchase of Investments	-130	-282	-777	-1,617	-984	-486
Divestitures	0.00	0.00	0.62	0.00	0.00	0.00
Sale and/or Maturity of Investments	76	199	529	1,205	1,090	680
Net Cash From Financing Activities	41	322	756	112	276	7.74
Net Cash From Continuing Financing Activities	41	322	756	112	276	7.74
Repayment of Debt	-0.46	-1.57	-	-2.29	-2.25	-0.49
Repurchase of Common Equity	-2.52	-2.06	-8.82	-0.19	-0.63	0.00
Issuance of Common Equity	0.00	320	757	111	273	2.62
Other Financing Activities, net	0.19	3.16	7.51	2.73	6.13	5.60
Cash Interest Paid	0.19	0.56	0.57	0.38	0.16	0.03

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-109	76	14	-19	-63	267	-150	4.62	-62	53	244
Net Cash From Operating Activities	-74	-69	-110	-85	-90	135	-100	-83	-88	-76	-104
Net Cash From Continuing Operating Activities	-74	-69	-110	-85	-90	135	-100	-83	-88	-76	-104
Net Income / (Loss) Continuing Operations	-110	-38	-96	-83	-96	143	-99	-91	-97	-90	-109
Consolidated Net Income / (Loss)	-110	-38	-96	-83	-96	143	-99	-91	-97	-90	-109
Depreciation Expense	3.47	3.94	4.65	4.82	5.19	5.36	5.43	5.58	5.48	5.44	5.53
Amortization Expense	-3.22	3.33	-6.93	-7.57	-7.88	2.17	-6.58	-5.93	-5.62	5.03	-3.85
Non-Cash Adjustments To Reconcile Net Income	32	4.11	31	26	35	7.81	35	33	31	21	29
Changes in Operating Assets and Liabilities, net	2.85	-42	-42	-25	-26	-23	-35	-25	-22	-17	-25
Net Cash From Investing Activities	-36	113	25	-41	-10	98	-53	87	25	126	-125
Net Cash From Continuing Investing Activities	-36	113	25	-41	-10	98	-53	87	25	126	-125
Purchase of Property, Plant & Equipment	-12	-8.26	-6.02	-16	-7.95	-3.59	-2.44	-1.96	-1.58	-2.97	-3.07
Purchase of Investments	-358	-238	-267	-391	-274	-53	-195	-134	-157	-	-339
Sale and/or Maturity of Investments	334	360	298	366	271	155	144	224	183	129	217
Net Cash From Financing Activities	1.56	32	98	108	37	34	2.90	0.13	1.26	3.44	473
Net Cash From Continuing Financing Activities	1.56	32	98	108	37	34	2.90	0.13	1.26	3.44	473
Repayment of Debt	-0.58	-0.59	-0.60	-0.62	-0.40	-0.63	-0.18	-0.11	-0.20	-	0.00
Repurchase of Common Equity	-0.03	-0.05	-0.06	-0.19	-0.38	-	0.00	-	-	-	0.00
Issuance of Common Equity	1.66	32	96	108	36	34	1.40	-	1.22	-0.00	473
Other Financing Activities, net	0.50	0.76	3.39	0.70	1.29	0.75	1.68	0.24	0.24	3.45	0.72
Cash Interest Paid	0.09	0.08	0.06	0.05	0.03	0.02	0.01	0.01	0.01	-	0.00

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	156	452	1,474	1,342	1,460	1,104
Total Current Assets	95	308	1,273	1,093	1,211	878
Cash & Equivalents	37	162	560	233	436	282
Short-Term Investments	55	138	406	845	754	569
Prepaid Expenses	2.70	8.65	7.36	15	21	27
Plant, Property, & Equipment, net	24	39	84	116	125	111
Total Noncurrent Assets	37	105	117	133	124	114
Other Noncurrent Operating Assets	37	105	117	133	124	114
Total Liabilities & Shareholders' Equity	156	452	1,474	1,342	1,460	1,104
Total Liabilities	55	206	648	608	478	370
Total Current Liabilities	29	102	213	224	206	182
Accounts Payable	7.85	6.31	7.47	9.03	1.62	3.87
Accrued Expenses	7.85	18	68	50	112	47
Current Deferred Revenue	-	0.02	86	136	69	109
Other Current Liabilities	13	78	52	29	24	22
Total Noncurrent Liabilities	26	104	434	385	273	188
Noncurrent Deferred Revenue	-	0.39	262	202	110	33
Other Noncurrent Operating Liabilities	22	103	172	182	163	155
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-201	246	827	733	981	734
Total Preferred & Common Equity	-201	246	827	733	981	734
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-201	246	827	733	981	734
Common Stock	1.92	643	1,595	1,793	2,171	2,299
Retained Earnings	-203	-398	-768	-1,057	-1,190	-1,567
Accumulated Other Comprehensive Income / (Loss)	0.02	-0.01	-0.05	-2.43	0.60	0.68

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	1,350	1,332	1,354	1,291	1,360	1,261	1,171	1,467
Total Current Assets	1,109	1,083	1,095	1,040	1,122	1,029	946	1,248
Cash & Equivalents	157	250	226	169	288	293	230	528
Short-Term Investments	938	810	847	846	807	715	696	692
Prepaid Expenses	14	24	22	24	27	21	20	28
Plant, Property, & Equipment, net	111	122	128	128	121	117	114	110
Total Noncurrent Assets	130	127	131	123	117	114	112	110
Other Noncurrent Operating Assets	130	127	131	123	117	114	112	110
Total Liabilities & Shareholders' Equity	1,350	1,332	1,354	1,291	1,360	1,261	1,171	1,467
Total Liabilities	636	571	542	512	446	407	380	344
Total Current Liabilities	239	220	210	220	187	177	166	142
Accounts Payable	7.02	14	6.89	3.18	2.79	4.43	3.81	7.70
Accrued Expenses	39	38	38	42	86	67	52	30
Current Deferred Revenue	160	143	139	153	72	85	89	85
Other Current Liabilities	33	25	26	22	26	21	21	18
Total Noncurrent Liabilities	397	351	333	291	259	230	214	202
Noncurrent Deferred Revenue	198	172	156	125	100	75	58	49
Other Noncurrent Operating Liabilities	199	179	177	167	160	154	156	153
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	714	762	812	779	913	854	791	1,123
Total Preferred & Common Equity	714	762	812	779	913	854	791	1,123
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	714	762	812	779	913	854	791	1,123
Common Stock	1,738	1,916	2,050	2,114	2,203	2,235	2,266	2,799
Retained Earnings	-1,019	-1,154	-1,237	-1,333	-1,289	-1,380	-1,476	-1,676
Accumulated Other Comprehensive Income / (Loss)	-4.67	-0.77	-2.02	-2.02	-0.92	-1.11	1.76	0.16

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	33.33%	215,916.67%	17.51%	520.01%	-83.18%
EBITDA Growth	0.00%	-144.69%	-90.39%	27.79%	32.12%	-134.19%
EBIT Growth	0.00%	-142.87%	-89.44%	25.67%	35.44%	-139.43%
NOPAT Growth	0.00%	-76.65%	-195.62%	13.76%	47.86%	-135.47%
Net Income Growth	0.00%	-148.44%	-90.47%	22.00%	54.16%	-184.28%
EPS Growth	0.00%	70.18%	-37.71%	28.42%	58.35%	-166.28%
Operating Cash Flow Growth	0.00%	-32.97%	30.78%	133.99%	-762.29%	-132.75%
Free Cash Flow Firm Growth	0.00%	0.00%	-650.28%	83.58%	-732.64%	-47.22%
Invested Capital Growth	0.00%	-500.58%	-156.72%	-148.12%	39.49%	43.80%
Revenue Q/Q Growth	0.00%	0.00%	6,538.16%	-33.75%	363.14%	-81.83%
EBITDA Q/Q Growth	0.00%	-53.80%	8.09%	8.54%	51.06%	-112.68%
EBIT Q/Q Growth	0.00%	-52.47%	7.66%	6.71%	49.89%	-121.29%
NOPAT Q/Q Growth	0.00%	-12.19%	-6.13%	-8.15%	55.69%	-127.49%
Net Income Q/Q Growth	0.00%	-53.25%	7.66%	8.36%	57.75%	-162.37%
EPS Q/Q Growth	0.00%	39.36%	14.90%	5.28%	58.75%	-189.87%
Operating Cash Flow Q/Q Growth	0.00%	-7.28%	28.28%	-75.92%	57.79%	-155.69%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-21.08%	-154.84%	38.53%	-66.23%
Invested Capital Q/Q Growth	0.00%	-2,417.92%	-33.40%	9.32%	11.83%	12.83%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-433,172.22%	-794,958.33%	-700.67%	-430.58%	-47.14%	-656.46%
Operating Margin	-417,522.22%	-553,166.67%	-757.01%	-555.61%	-46.73%	-654.25%
EBIT Margin	-447,522.22%	-815,179.17%	-714.89%	-452.19%	-47.08%	-670.36%
Profit (Net Income) Margin	-435,144.44%	-810,800.00%	-714.91%	-474.54%	-35.09%	-593.13%
Tax Burden Percent	100.00%	100.00%	100.00%	111.11%	101.04%	100.01%
Interest Burden Percent	97.23%	99.46%	100.00%	94.45%	73.75%	88.47%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-389.46%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-360.04%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	311.86%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-77.59%	-112.32%	-69.13%	-37.06%	-15.46%	-43.94%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-51.60%	-64.38%	-38.48%	-19.56%	-12.70%	-33.22%
Return on Assets (ROA)	-50.18%	-64.03%	-38.49%	-20.53%	-9.46%	-29.39%
Return on Common Equity (ROCE)	154.58%	-14.41%	-69.13%	-37.06%	-15.46%	-43.94%
Return on Equity Simple (ROE_SIMPLE)	38.95%	-79.24%	-44.83%	-39.41%	-13.50%	-51.36%
Net Operating Profit after Tax (NOPAT)	-53	-93	-275	-237	-124	-291
NOPAT Margin	-292,265.56%	-387,216.67%	-529.91%	-388.93%	-32.71%	-457.98%
Net Nonoperating Expense Percent (NNEP)	-29.41%	-52.52%	-15.16%	-5.10%	-0.79%	-8.41%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-32.30%	-12.59%	-39.66%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	114,183.33%	123,354.17%	110.37%	144.13%	30.93%	175.58%
R&D to Revenue	303,438.89%	429,912.50%	746.64%	511.48%	115.80%	578.67%
Operating Expenses to Revenue	417,622.22%	553,266.67%	857.01%	655.61%	146.73%	754.25%
Earnings before Interest and Taxes (EBIT)	-81	-196	-371	-275	-178	-426
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-78	-191	-363	-262	-178	-417
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	19.27	6.57	3.76	2.26	2.80
Price to Tangible Book Value (P/TBV)	0.00	19.27	6.57	3.76	2.26	2.80
Price to Revenue (P/Rev)	10,000.00	197,180.98	104.73	45.24	5.87	32.33
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	29.21	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	21,922.89	184,694.69	86.11	27.54	2.72	18.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	74.48	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.04	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.04	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.87	-1.12	-1.18	-1.31	-1.32	-1.19
Leverage Ratio	1.55	1.75	1.80	1.81	1.63	1.49
Compound Leverage Factor	1.50	1.74	1.80	1.70	1.20	1.32
Debt to Total Capital	4.19%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	4.19%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	286.69%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-190.88%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.06	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.12	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.06	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.08	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.66	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.08	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.06	11.66	4.37	1.76	2.32	0.88
Noncontrolling Interest Sharing Ratio	299.22%	87.17%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	3.24	3.01	5.96	4.89	5.89	4.82
Quick Ratio	3.15	2.93	4.52	4.82	5.79	4.67
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-25	-190	-31	-260	-382
Operating Cash Flow to CapEx	-575.20%	-585.32%	-141.57%	46.02%	-442.30%	-3,881.58%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-21,102.94	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	-7,363.11	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-12,564.33	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.05	0.04	0.27	0.05
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.84	0.61	3.14	0.54
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	14	-54	-139	-345	-209	-117
Invested Capital Turnover	0.00	0.00	-0.54	-0.25	-1.37	-0.39
Increase / (Decrease) in Invested Capital	0.00	-68	-85	-206	136	91
Enterprise Value (EV)	395	4,433	4,464	1,678	1,029	1,203
Market Capitalization	180	4,732	5,430	2,756	2,219	2,054
Book Value per Share	($31.04)	$4.24	$12.13	$10.41	$12.04	$8.86
Tangible Book Value per Share	($31.04)	$4.24	$12.13	$10.41	$12.04	$8.86
Total Capital	105	246	827	733	981	734
Total Debt	4.41	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	4.41	0.00	0.00	0.00	0.00	0.00
Net Debt	-87	-300	-966	-1,078	-1,190	-851
Capital Expenditures (CapEx)	13	16	47	49	34	8.95
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-26	-94	94	-209	-184	-155
Debt-free Net Working Capital (DFNWC)	65	206	1,060	869	1,005	696
Net Working Capital (NWC)	65	206	1,060	869	1,005	696
Net Nonoperating Expense (NNE)	26	102	96	52	8.99	86
Net Nonoperating Obligations (NNO)	-87	-300	-966	-1,078	-1,190	-851
Total Depreciation and Amortization (D&A)	2.58	4.85	7.38	13	-0.21	8.83
Debt-free, Cash-free Net Working Capital to Revenue	-146,900.00%	-390,362.50%	181.17%	-342.80%	-48.82%	-243.49%
Debt-free Net Working Capital to Revenue	363,366.67%	858,266.67%	2,043.77%	1,426.96%	266.20%	1,095.88%
Net Working Capital to Revenue	363,366.67%	858,266.67%	2,043.77%	1,426.96%	266.20%	1,095.88%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($4.19)	($5.77)	($4.13)	($1.72)	($4.58)
Adjusted Weighted Average Basic Shares Outstanding	0.00	62.42M	64.23M	70.02M	77.15M	82.31M
Adjusted Diluted Earnings per Share	$0.00	($4.19)	($5.77)	($4.13)	($1.72)	($4.58)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	62.42M	64.23M	70.02M	77.15M	82.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	($4.19)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	46.73M	68.73M	72.40M	81.66M	83.69M
Normalized Net Operating Profit after Tax (NOPAT)	-53	-93	-275	-237	-124	-291
Normalized NOPAT Margin	-292,265.56%	-387,216.67%	-529.91%	-388.93%	-32.71%	-457.98%
Pre Tax Income Margin	-435,144.44%	-810,800.00%	-714.91%	-427.08%	-34.73%	-593.07%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-41,181.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	-30,525.06	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	-46,382.22	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	-35,726.28	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3.22%	-1.06%	-2.38%	-0.07%	-0.48%	0.00%

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1,970.64%	-60.76%	187.10%	20.80%	8.82%	1,478.04%	-69.39%	-41.48%	-17.01%	-90.49%	0.81%
EBITDA Growth	-227.21%	39.38%	-62.40%	-36.74%	-29.04%	470.48%	-2.72%	-8.27%	2.28%	-165.04%	-5.16%
EBIT Growth	-208.06%	30.58%	-52.34%	-27.99%	-25.55%	393.81%	-3.85%	-11.06%	-0.01%	-176.67%	-7.77%
NOPAT Growth	-31.12%	-40.17%	-29.78%	-24.62%	-18.58%	313.29%	-5.26%	-2.69%	1.63%	-152.71%	-14.55%
Net Income Growth	-289.70%	40.73%	-39.36%	-15.05%	12.31%	472.36%	-2.29%	-10.00%	-0.60%	-163.27%	-10.74%
EPS Growth	-271.43%	29.87%	-31.68%	-5.88%	21.79%	453.70%	9.02%	-2.78%	4.10%	-157.07%	-2.48%
Operating Cash Flow Growth	-2,577.42%	-3,880.93%	-150.26%	-61.97%	-20.52%	295.22%	9.17%	1.96%	1.85%	-156.54%	-4.15%
Free Cash Flow Firm Growth	298.29%	255.45%	-163.61%	-182.89%	-203.45%	-102.27%	-15.15%	-2.64%	19.48%	-4,857.85%	11.62%
Invested Capital Growth	-265.01%	-148.12%	24.28%	28.58%	37.77%	39.49%	39.23%	41.05%	43.16%	43.80%	46.53%
Revenue Q/Q Growth	-5.12%	26.82%	20.82%	-16.90%	-14.53%	1,739.07%	-97.66%	58.87%	21.21%	110.72%	-75.16%
EBITDA Q/Q Growth	-21.18%	56.38%	-135.71%	10.32%	-14.36%	225.24%	-185.82%	5.47%	-3.21%	16.64%	-29.31%
EBIT Q/Q Growth	-17.07%	48.11%	-136.70%	10.99%	-14.84%	221.43%	-183.66%	4.81%	-3.42%	6.91%	-17.60%
NOPAT Q/Q Growth	-11.39%	2.54%	-11.17%	-3.25%	-5.99%	275.30%	-154.86%	-0.73%	-1.53%	6.07%	-19.24%
Net Income Q/Q Growth	-52.29%	65.00%	-151.53%	14.19%	-16.08%	248.61%	-169.10%	7.72%	-6.17%	6.53%	-20.94%
EPS Q/Q Growth	-52.94%	65.38%	-146.30%	18.80%	-12.96%	256.56%	-163.35%	8.26%	-5.41%	6.84%	-13.76%
Operating Cash Flow Q/Q Growth	-42.51%	7.12%	-58.71%	22.90%	-6.04%	250.44%	-173.85%	16.78%	-6.16%	13.34%	-36.04%
Free Cash Flow Firm Q/Q Growth	-0.18%	-32.34%	-214.89%	-6.84%	-24.57%	98.52%	-5,730.83%	4.78%	2.27%	8.63%	-3.95%
Invested Capital Q/Q Growth	-3.86%	9.32%	13.55%	12.28%	9.51%	11.83%	13.18%	14.91%	12.74%	12.83%	17.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-546.81%	-188.09%	-449.05%	-484.62%	-648.42%	44.16%	-1,506.92%	-896.64%	-763.49%	-302.03%	-1,571.99%
Operating Margin	-577.90%	-444.10%	-408.66%	-507.79%	-629.72%	42.02%	-1,405.29%	-891.06%	-746.40%	-332.71%	-1,596.87%
EBIT Margin	-548.43%	-224.38%	-439.61%	-470.91%	-632.73%	41.78%	-1,491.47%	-893.66%	-762.46%	-336.85%	-1,594.47%
Profit (Net Income) Margin	-693.56%	-191.39%	-398.46%	-411.49%	-558.88%	45.16%	-1,331.57%	-773.45%	-677.47%	-300.51%	-1,462.78%
Tax Burden Percent	134.18%	102.68%	0.00%	100.00%	100.00%	299.35%	0.00%	100.04%	100.00%	47.80%	100.00%
Interest Burden Percent	94.25%	83.07%	0.00%	87.38%	88.33%	36.11%	0.00%	86.51%	88.85%	186.63%	91.74%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-40.23%	-37.06%	-39.78%	-40.60%	-42.01%	-15.46%	-16.09%	-17.17%	-18.29%	-43.94%	-38.04%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-40.23%	-9.71%	-24.21%	-27.23%	-39.08%	11.27%	-399.90%	-240.96%	-216.57%	-16.69%	-71.73%
Return on Assets (ROA)	-50.88%	-8.28%	-21.94%	-23.80%	-34.52%	12.18%	-357.02%	-208.55%	-192.43%	-14.89%	-65.80%
Return on Common Equity (ROCE)	-40.23%	-37.06%	-39.78%	-40.60%	-42.01%	-15.46%	-16.09%	-17.17%	-18.29%	-43.94%	-38.04%
Return on Equity Simple (ROE_SIMPLE)	-44.15%	0.00%	-41.54%	-40.31%	-40.27%	0.00%	-14.75%	-16.74%	-18.15%	0.00%	-34.49%
Net Operating Profit after Tax (NOPAT)	-64	-62	-69	-72	-76	133	-73	-73	-75	-70	-84
NOPAT Margin	-404.53%	-310.87%	-286.06%	-355.46%	-440.80%	42.02%	-983.70%	-623.74%	-522.48%	-232.90%	-1,117.81%
Net Nonoperating Expense Percent (NNEP)	-4.45%	2.34%	-2.38%	-1.01%	-1.92%	0.88%	-2.39%	-1.69%	-2.28%	-1.99%	-2.23%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.49%	-	-	-	13.54%	-	-	-	-9.55%	-7.43%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	138.08%	113.20%	97.03%	122.57%	147.79%	13.68%	360.65%	251.67%	185.82%	95.32%	374.03%
R&D to Revenue	539.83%	430.91%	411.62%	485.23%	581.92%	44.30%	1,144.64%	739.39%	660.58%	337.39%	1,322.84%
Operating Expenses to Revenue	677.90%	544.10%	508.66%	607.79%	729.72%	57.98%	1,505.29%	991.06%	846.40%	432.71%	1,697.23%
Earnings before Interest and Taxes (EBIT)	-87	-45	-106	-95	-109	132	-111	-105	-109	-101	-119
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-86	-38	-109	-97	-111	140	-112	-106	-109	-91	-117
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.69	3.76	2.91	3.00	2.45	2.26	2.95	2.26	2.55	2.80	1.46
Price to Tangible Book Value (P/TBV)	4.69	3.76	2.91	3.00	2.45	2.26	2.95	2.26	2.55	2.80	1.46
Price to Revenue (P/Rev)	36.45	45.24	28.90	30.36	23.36	5.87	7.46	5.47	5.78	32.33	25.71
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	24.55	27.54	15.09	16.97	10.90	2.72	4.43	2.61	3.13	18.94	6.52
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	24.13	74.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	39.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.31	-1.31	-1.43	-1.39	-1.41	-1.32	-1.29	-1.25	-1.24	-1.19	-1.14
Leverage Ratio	1.60	1.81	1.75	1.72	1.77	1.63	1.61	1.57	1.57	1.49	1.39
Compound Leverage Factor	1.51	1.50	0.00	1.50	1.56	0.59	0.00	1.36	1.39	2.79	1.27
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.74	2.33	1.69	2.03	1.33	3.03	3.12	2.13	2.21	1.85	1.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.64	4.89	4.92	5.22	4.72	5.89	5.99	5.81	5.69	4.82	8.81
Quick Ratio	4.58	4.82	4.82	5.12	4.61	5.79	5.85	5.69	5.57	4.67	8.62
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	212	143	-165	-176	-219	-3.26	-190	-181	-177	-161	-168
Operating Cash Flow to CapEx	-632.02%	-837.56%	-1,825.08%	-523.36%	-1,129.64%	3,763.53%	-4,091.35%	-4,232.99%	-5,588.14%	-2,571.21%	-3,389.36%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.07	0.04	0.06	0.06	0.06	0.27	0.27	0.27	0.28	0.05	0.05
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.01	0.61	0.71	0.68	0.68	3.14	2.97	2.87	2.90	0.54	0.55
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-380	-345	-298	-261	-237	-209	-181	-154	-134	-117	-97
Invested Capital Turnover	-0.38	-0.25	-0.22	-0.26	-0.26	-1.37	-1.51	-1.70	-1.89	-0.39	-0.46
Increase / (Decrease) in Invested Capital	-276	-206	96	105	144	136	117	107	102	91	84
Enterprise Value (EV)	2,257	1,678	1,157	1,361	889	1,029	1,598	920	1,093	1,203	414
Market Capitalization	3,352	2,756	2,217	2,434	1,905	2,219	2,693	1,929	2,019	2,054	1,634
Book Value per Share	$10.16	$10.41	$10.52	$10.65	$9.84	$12.04	$11.18	$10.38	$9.60	$8.86	$13.42
Tangible Book Value per Share	$10.16	$10.41	$10.52	$10.65	$9.84	$12.04	$11.18	$10.38	$9.60	$8.86	$13.42
Total Capital	714	733	762	812	779	981	913	854	791	734	1,123
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,095	-1,078	-1,059	-1,073	-1,015	-1,190	-1,095	-1,008	-926	-851	-1,220
Capital Expenditures (CapEx)	12	8.26	6.02	16	7.95	3.59	2.44	1.96	1.58	2.97	3.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-225	-209	-196	-188	-196	-184	-160	-156	-146	-155	-114
Debt-free Net Working Capital (DFNWC)	870	869	863	885	819	1,005	934	852	779	696	1,106
Net Working Capital (NWC)	870	869	863	885	819	1,005	934	852	779	696	1,106
Net Nonoperating Expense (NNE)	46	-24	27	11	20	-9.94	26	18	22	20	26
Net Nonoperating Obligations (NNO)	-1,095	-1,078	-1,059	-1,073	-1,015	-1,190	-1,095	-1,008	-926	-851	-1,220
Total Depreciation and Amortization (D&A)	0.26	7.27	-2.29	-2.76	-2.70	7.53	-1.15	-0.35	-0.15	10	1.68
Debt-free, Cash-free Net Working Capital to Revenue	-244.15%	-342.80%	-256.03%	-234.22%	-240.68%	-48.82%	-44.35%	-44.26%	-41.89%	-243.49%	-179.12%
Debt-free Net Working Capital to Revenue	946.20%	1,426.96%	1,125.36%	1,104.38%	1,004.46%	266.20%	258.93%	241.69%	222.88%	1,095.88%	1,739.70%
Net Working Capital to Revenue	946.20%	1,426.96%	1,125.36%	1,104.38%	1,004.46%	266.20%	258.93%	241.69%	222.88%	1,095.88%	1,739.70%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.56)	($0.54)	($1.33)	($1.08)	($1.22)	$1.91	($1.21)	($1.11)	($1.17)	($1.09)	($1.24)
Adjusted Weighted Average Basic Shares Outstanding	70.34M	70.02M	72.27M	76.34M	79.02M	77.15M	81.70M	82.31M	82.41M	82.31M	87.98M
Adjusted Diluted Earnings per Share	($1.56)	($0.54)	($1.33)	($1.08)	($1.22)	$1.91	($1.21)	($1.11)	($1.17)	($1.09)	($1.24)
Adjusted Weighted Average Diluted Shares Outstanding	70.34M	70.02M	72.27M	76.34M	79.02M	77.15M	81.70M	82.31M	82.41M	82.31M	87.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	70.47M	72.40M	76.22M	79.20M	81.50M	81.66M	82.31M	82.42M	82.81M	83.69M	100.56M
Normalized Net Operating Profit after Tax (NOPAT)	-64	-62	-69	-72	-76	93	-73	-73	-75	-70	-83
Normalized NOPAT Margin	-404.53%	-310.87%	-286.06%	-355.46%	-440.80%	29.41%	-983.70%	-623.74%	-522.48%	-232.90%	-1,117.55%
Pre Tax Income Margin	-516.90%	-186.40%	0.00%	-411.49%	-558.88%	15.09%	0.00%	-773.12%	-677.47%	-628.67%	-1,462.78%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.08%	-0.07%	-0.08%	-0.10%	-0.22%	-0.48%	-0.42%	-0.27%	0.00%	0.00%	0.00%

Frequently Asked Questions About Beam Therapeutics' Financials

When does Beam Therapeutics's financial year end?

According to the most recent income statement we have on file, Beam Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Beam Therapeutics' net income changed over the last 5 years?

Beam Therapeutics' net income appears to be on an upward trend, with a most recent value of -$376.74 million in 2024, rising from -$78.33 million in 2019. The previous period was -$132.53 million in 2023. See where experts think Beam Therapeutics is headed by visiting Beam Therapeutics' forecast page.

What is Beam Therapeutics's operating income?

Beam Therapeutics's total operating income in 2024 was -$415.57 million, based on the following breakdown:

Total Gross Profit: $63.52 million
Total Operating Expenses: $479.09 million

How has Beam Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Beam Therapeutics' total revenue changed from $18 thousand in 2019 to $63.52 million in 2024, a change of 352,777.8%.

How much debt does Beam Therapeutics have?

Beam Therapeutics' total liabilities were at $370.28 million at the end of 2024, a 22.6% decrease from 2023, and a 571.4% increase since 2019.

How much cash does Beam Therapeutics have?

In the past 5 years, Beam Therapeutics' cash and equivalents has ranged from $37.22 million in 2019 to $559.99 million in 2021, and is currently $281.97 million as of their latest financial filing in 2024.

How has Beam Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Beam Therapeutics' book value per share changed from -31.04 in 2019 to 8.86 in 2024, a change of -128.5%.

Related Companies

This page (NASDAQ:BEAM) was last updated on 6/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beam Therapeutics (BEAM) Financials

Frequently Asked Questions About Beam Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beam Therapeutics (BEAM) Financials

Annual Income Statements for Beam Therapeutics

Quarterly Income Statements for Beam Therapeutics

Annual Cash Flow Statements for Beam Therapeutics

Quarterly Cash Flow Statements for Beam Therapeutics

Annual Balance Sheets for Beam Therapeutics

Quarterly Balance Sheets for Beam Therapeutics

Annual Metrics And Ratios for Beam Therapeutics

Quarterly Metrics And Ratios for Beam Therapeutics

Frequently Asked Questions About Beam Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools